Callan Family Office LLC Invests $1.22 Million in United Therapeutics Corporation $UTHR

Callan Family Office LLC bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, HoldingsChannel reports. The institutional investor bought 2,246 shares of the biotechnology company’s stock, valued at approximately $1,217,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Leuthold Group LLC increased its position in shares of United Therapeutics by 41.4% during the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after purchasing an additional 3,126 shares during the last quarter. UBS Group AG raised its stake in shares of United Therapeutics by 45.3% during the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after purchasing an additional 70,445 shares during the period. Nicholas Investment Partners LP boosted its holdings in shares of United Therapeutics by 478.5% in the 4th quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock worth $2,218,000 after buying an additional 3,766 shares during the last quarter. M&T Bank Corp boosted its holdings in shares of United Therapeutics by 171.6% in the 4th quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company’s stock worth $1,531,000 after buying an additional 1,985 shares during the last quarter. Finally, Seven Fleet Capital Management LP bought a new position in United Therapeutics during the fourth quarter valued at about $633,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $547.61, for a total value of $5,202,295.00. Following the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at $22,185,323.93. The trade was a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,311,581.28. The trade was a 34.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 434,075 shares of company stock valued at $233,942,595 in the last quarter. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Stock Performance

UTHR stock opened at $512.88 on Tuesday. The company has a market capitalization of $22.00 billion, a price-to-earnings ratio of 18.35, a PEG ratio of 1.74 and a beta of 0.59. United Therapeutics Corporation has a fifty-two week low of $302.19 and a fifty-two week high of $609.35. The stock has a fifty day moving average of $532.35 and a 200-day moving average of $538.04.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter last year, the firm posted $6.41 EPS. Equities analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current year.

Analyst Ratings Changes

UTHR has been the subject of a number of research analyst reports. Bank of America decreased their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research note on Thursday, August 6th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. JPMorgan Chase & Co. raised their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Finally, Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $646.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.